Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Sorafenib (Nexavar, BAY43-9006)|DRUG: Placebo|DRUG: Capecitabine
Sponsor: Bayer
Collaborators: Onyx Therapeutics, Inc.